# Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma

> **NCT07514793** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 37 (estimated)

## Conditions studied

- Mesothelioma

## Interventions

- **DRUG:** Iparomlimab and Tuvoraleimab injection+Bevacizumab+Pemetrexed+Cisplatin

## Key facts

- **NCT ID:** NCT07514793
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2029-04
- **Final completion:** 2029-04
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07514793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07514793, "Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT07514793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*